Ignored "IF": search terms need at least 3 characters.
The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).
The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
It is very uncertain whether the intervention changes all‐cause mortality at 10 days ‐ short‐term treatment (very low certainty).
Short‐course L‐AmB + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of L‐AmB + FLU (low certainty).
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
Valaciclovir (short‐term) showed no clear difference in viral load (shedding) in saliva compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).
Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (moderate certainty).
Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (low certainty).
Short duration (3 to 4 days) showed no clear difference in persistent bacteriuria after treatment compared with long duration (7 to 14 days) IV therapy (low certainty).
Short duration (3 to 4 days) showed no clear difference in recurrent UTI within 6 months compared with long duration (7 to 14 days) IV therapy (moderate certainty).
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: all included children with… compared with long duration (7 to 14 days) IV therapy (moderate certainty).
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: children with initial… compared with long duration (7 to 14 days) IV therapy (moderate certainty).